PUBLICATIONS
2010
Benkler C, Offen D, Melamed E, Kupershmidt L, Amit T, Mandel S, Youdim MB, Weinreb O.
EPMA J. 2010 Jun;1(2):343-61. doi: 10.1007/s13167-010-0026-1.
Neurogenesis in the aged and neurodegenerative brain.
Shruster A, Melamed E, Offen D.
Apoptosis. 2010 Nov;15(11):1415-21. doi: 10.1007/s10495-010-0491-y. Review.
Shemesh N, Sadan O, Melamed E, Offen D, Cohen Y.
NMR Biomed. 2010 Feb;23(2):196-206. doi: 10.1002/nbm.1443.
Barhum Y, Gai-Castro S, Bahat-Stromza M, Barzilay R, Melamed E, Offen D.
J Mol Neurosci. 2010 May;41(1):129-37. doi: 10.1007/s12031-009-9302-8.
2009
Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases.
Sadan O, Melamed E, Offen D.
Expert Opin Biol Ther. 2009 Dec;9(12):1487-97. doi: 10.1517/14712590903321439. Review.
Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D.
Isr Med Assoc J. 2009 Apr;11(4):201-4.
Barzilay R, Melamed E, Offen D.
Stem Cells. 2009 Oct;27(10):2509-15. doi: 10.1002/stem.172. Review.
Barzilay R, Sadan O, Melamed E, Offen D.
Cytotherapy. 2009;11(4):435-42. doi: 10.1080/14653240902849796.
Grunberg-Etkovitz N, Lev N, Ickowicz D, Avital A, Offen D, Malik Z.
J Environ Pathol Toxicol Oncol. 2009;28(1):5-24.
Barzilay R, Ben-Zur T, Bulvik S, Melamed E, Offen D.
Stem Cells Dev. 2009 May;18(4):591-601. doi: 10.1089/scd.2008.0138.
Sadan O, Bahat-Stromza M, Barhum Y, Levy YS, Pisnevsky A, Peretz H, Ilan AB, Bulvik S, Shemesh N, Krepel D, Cohen Y, Melamed E, Offen D.
Stem Cells Dev. 2009 Oct;18(8):1179-90. doi: 10.1089/scd.2008.0411.
Bahat-Stroomza M, Barhum Y, Levy YS, Karpov O, Bulvik S, Melamed E, Offen D.
J Mol Neurosci. 2009 Sep;39(1-2):199-210. doi: 10.1007/s12031-008-9166-3.
DJ-1 protects against dopamine toxicity.
Lev N, Ickowicz D, Barhum Y, Lev S, Melamed E, Offen D.
J Neural Transm (Vienna). 2009 Feb;116(2):151-60. doi: 10.1007/s00702-008-0134-4.
DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS.
Lev N, Ickowicz D, Barhum Y, Melamed E, Offen D.
J Mol Neurosci. 2009 Jun;38(2):94-102. doi: 10.1007/s12031-008-9138-7.
Offen D, Barhum Y, Melamed E, Embacher N, Schindler C, Ransmayr G.
J Mol Neurosci. 2009 Jun;38(2):85-93. doi: 10.1007/s12031-007-9004-z.
2008
Dratviman-Storobinsky O, Hasanreisoglu M, Offen D, Barhum Y, Weinberger D, Goldenberg-Cohen N.
Mol Vis. 2008;14:2171-9.
Sadan O, Shemesh N, Barzilay R, Bahat-Stromza M, Melamed E, Cohen Y, Offen D.
Stem Cells. 2008 Oct;26(10):2542-51. doi: 10.1634/stemcells.2008-0240.
Levy YS, Bahat-Stroomza M, Barzilay R, Burshtein A, Bulvik S, Barhum Y, Panet H, Melamed E, Offen D.
Cytotherapy. 2008;10(4):340-52. doi: 10.1080/14653240802021330.
Barzilay R, Kan I, Ben-Zur T, Bulvik S, Melamed E, Offen D.
Stem Cells Dev. 2008 Jun;17(3):547-54. doi: 10.1089/scd.2007.0172.
Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection.
Lev N, Ickowicz D, Melamed E, Offen D.
Neurotoxicology. 2008 May;29(3):397-405. doi: 10.1016/j.neuro.2008.01.007.
2007
Lev N, Melamed E, Offen D.
Handb Clin Neurol. 2007;84:385-98. doi: 10.1016/S0072-9752(07)84050-4.
Offen D, Barhum Y, Levy YS, Burshtein A, Panet H, Cherlow T, Melamed E.
J Neural Transm Suppl. 2007;(72):133-43.
Role of DJ-1 in parkinson's disease.
Lev N, Roncevich D, Ickowicz D, Melamed E, Offen D.
J Mol Neurosci. 2007 Mar;31(3):307.
Bax ablation protects against hepatic ischemia/reperfusion injury in transgenic mice.
Ben-Ari Z, Pappo O, Cheporko Y, Yasovich N, Offen D, Shainberg A, Leshem D, Sulkes J, Vidne BA, Hochhauser E.
Liver Transpl. 2007 Aug;13(8):1181-8.
Autotransplantation of bone marrow-derived stem cells as a therapy for neurodegenerative diseases.
Kan I, Melamed E, Offen D.
Handb Exp Pharmacol. 2007;(180):219-42. Review.
Kan I, Ben-Zur T, Barhum Y, Levy YS, Burstein A, Charlow T, Bulvik S, Melamed E, Offen D.
Neurosci Lett. 2007 May 23;419(1):28-33. Epub 2007 Apr 13.
Bax deficiency reduces infarct size and improves long-term function after myocardial infarction.
Hochhauser E, Cheporko Y, Yasovich N, Pinchas L, Offen D, Barhum Y, Pannet H, Tobar A, Vidne BA, Birk E.
Cell Biochem Biophys. 2007;47(1):11-20.
Kan I, Melamed E, Offen D, Green P.
J Lipid Res. 2007 Mar;48(3):513-7.
Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model.
Grunfeld JF, Barhum Y, Blondheim N, Rabey JM, Melamed E, Offen D.
Exp Neurol. 2007 Mar;204(1):260-3.
2006
Lev N, Ickowicz D, Barhum Y, Blondheim N, Melamed E, Offen D.
Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):1987-95.
Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state.
Gilgun-Sherki Y, Melamed E, Offen D.
Curr Pharm Des. 2006;12(27):3509-19. Review.
Human mesenchymal stem cells express neural genes, suggesting a neural predisposition.
Blondheim NR, Levy YS, Ben-Zur T, Burshtein A, Cherlow T, Kan I, Barzilai R, Bahat-Stromza M, Barhum Y, Bulvik S, Melamed E, Offen D.
Stem Cells Dev. 2006 Apr;15(2):141-64.
Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
Lev N, Melamed E, Offen D.
Neurosci Lett. 2006 May 15;399(1-2):27-32. Epub 2006 Apr 11.
Adult stem cells for neuronal repair.
Barzilay R, Levy YS, Melamed E, Offen D.
Isr Med Assoc J. 2006 Jan;8(1):61-6. Review.
Hellmann MA, Panet H, Barhum Y, Melamed E, Offen D.
Neurosci Lett. 2006 Mar 6;395(2):124-8. Epub 2005 Dec 15.
2005
Sadan O, Bahat-Stromza M, Gilgun-Sherki Y, Atlas D, Melamed E, Offen D.
Clin Neuropharmacol. 2005 Nov-Dec;28(6):285-8.
Gilgun-Sherki Y, Barhum Y, Atlas D, Melamed E, Offen D.
J Mol Neurosci. 2005;27(1):125-35.
Therapeutic potential of neurotrophic factors in neurodegenerative diseases.
Levy YS, Gilgun-Sherki Y, Melamed E, Offen D.
BioDrugs. 2005;19(2):97-127. Review.
Bahat-Stroomza M, Gilgun-Sherki Y, Offen D, Panet H, Saada A, Krool-Galron N, Barzilai A, Atlas D, Melamed E.
Eur J Neurosci. 2005 Feb;21(3):637-46.
Integral therapeutic potential of bone marrow mesenchymal stem cells.
Kan I, Melamed E, Offen D.
Curr Drug Targets. 2005 Feb;6(1):31-41. Review.
2004
Elkon H, Melamed E, Offen D.
J Mol Neurosci. 2004;24(3):387-400.
Embryonic and adult stem cells as a source for cell therapy in Parkinson's disease.
Levy YS, Stroomza M, Melamed E, Offen D.
J Mol Neurosci. 2004;24(3):353-86. Review.
Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D.
Pharmacogenomics J. 2004;4(5):291-306. Review.
Offen D, Gilgun-Sherki Y, Barhum Y, Benhar M, Grinberg L, Reich R, Melamed E, Atlas D.
J Neurochem. 2004 Jun;89(5):1241-51.
Bax-ablation attenuates experimental autoimmune encephalomyelitis in mice.
Lev N, Barhum Y, Melamed E, Offen D.
Neurosci Lett. 2004 Apr 15;359(3):139-42.
Gilgun-Sherki Y, Melamed E, Offen D.
J Neurol. 2004 Mar;251(3):261-8. Review.
2003
Levy YS, Merims D, Panet H, Barhum Y, Melamed E, Offen D.
J Mol Neurosci. 2003;21(2):121-32.
Gilgun-Sherki Y, Panet H, Melamed E, Offen D.
Brain Res. 2003 Nov 7;989(2):196-204.
Gilgun-Sherki Y, Panet H, Holdengreber V, Mosberg-Galili R, Offen D.
Neurosci Res. 2003 Oct;47(2):201-7.
Antioxidant treatment in Alzheimer's disease: current state.
Gilgun-Sherki Y, Melamed E, Offen D.
J Mol Neurosci. 2003;21(1):1-11. Review.
Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D.
Pharmacol Toxicol. 2003 Aug;93(2):66-70.
Gilgun-Sherki Y, Melamed E, Ziv I, Offen D.
Pharmacol Toxicol. 2003 Jul;93(1):54-6.
Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice.
Hochhauser E, Kivity S, Offen D, Maulik N, Otani H, Barhum Y, Pannet H, Shneyvays V, Shainberg A, Goldshtaub V, Tobar A, Vidne BA.
Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H2351-9.
Apoptosis and Parkinson's disease.
Lev N, Melamed E, Offen D.
Prog Neuropsychopharmacol Biol Psychiatry. 2003 Apr;27(2):245-50. Review.
The molecular mechanisms of dopamine toxicity.
Barzilai A, Daily D, Zilkha-Falb R, Ziv I, Offen D, Melamed E, Shirvan A.
Adv Neurol. 2003;91:73-82. Review.
2002
Levy YS, Streifler JY, Panet H, Melamed E, Offen D.
Neurotox Res. 2002 Nov-Dec;4(7-8):609-616.
Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase.
Elkon H, Don J, Melamed E, Ziv I, Shirvan A, Offen D.
J Mol Neurosci. 2002 Jun;18(3):229-38.
Antioxidant therapy in acute central nervous system injury: current state.
Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D.
Pharmacol Rev. 2002 Jun;54(2):271-84. Review.
2001
Elkon H, Melamed E, Offen D.
Cell Mol Neurobiol. 2001 Dec;21(6):771-81.
Offen D, Shtaif B, Hadad D, Weizman A, Melamed E, Gil-Ad I.
Neurosci Lett. 2001 Dec 28;316(3):129-32.
Gilgun-Sherki Y, Melamed E, Offen D.
Neuropharmacology. 2001 Jun;40(8):959-75. Review.
Panet H, Barzilai A, Daily D, Melamed E, Offen D.
J Neurochem. 2001 Apr;77(2):391-8.
Catechol-O-methyltransferase decreases levodopa toxicity in vitro.
Offen D, Panet H, Galili-Mosberg R, Melamed E.
Clin Neuropharmacol. 2001 Jan-Feb;24(1):27-30.
Daily D, Vlamis-Gardikas A, Offen D, Mittelman L, Melamed E, Holmgren A, Barzilai A.
J Biol Chem. 2001 Jun 15;276(24):21618-26.
Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S.
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2837-42.
Molecular biology of dopamine-induced apoptosis : possible implications for Parkinson's disease.
Ziv I, Shirvan A, Offen D, Barzilai A, Melamed E.
Methods Mol Med. 2001;62:73-87. doi: 10.1385/1-59259-142-6:73.